Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens

Abstract

The myelin-associated protein Nogo-A has received more research attention than any other inhibitor of axonal regeneration in the injured central nervous system (CNS). Circumvention of its inhibitory effect, by using antibodies specific to Nogo-A, has been shown to promote axonal regrowth. Studies in our laboratory have demonstrated that active or passive immunization of CNS-injured rats or mice with myelin-associated peptides induces a T-cellmediated protective autoimmune response, which promotes recovery by reducing posttraumatic degeneration. Here, we show that neuronal degeneration after incomplete spinal-cord contusion in rats was substantially reduced, and hence recovery was significantly promoted, by posttraumatic immunization with p472, a peptide derived from Nogo-A. The observed effect seemed to be mediated by T cells and could be reproduced by passive transfer of a T cell line directed against the Nogo-A peptide. Thus, it seems that after incomplete spinal-cord injury, immunization with a variety of myelin-associated peptides, including those derived from Nogo-A, can be used to evoke a T cell-mediated response that promotes recovery. The choice of peptide(s) for clinical treatment of spinalcord injuries should be based on safety considerations; in particular, the likelihood that the chosen peptide will not cause an autoimmune disease or interfere with essential functions of this peptide or other proteins. From a therapeutic point of view, the fact that the active cellular agents are T cells rather than antibodies is an advantage, as T cell production commences within the time window required for a protective effect after spinal-cord injury, whereas antibody production takes longer.

The Tissue-Specific Self-Pathogen Is the Protective Self-Antigen: The Case of Uveitis

“…6). Under the same experimental conditions in this model, vaccination with a pathogenic peptide derived from myelin basic protein led to better recovery than that seen in nonvaccinated rats (10,24,32).…”

Quantitative1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease

“…Vaccination can also attenuate neuronal injury by affecting microglial responses (Moalem et al, 1999;Hammarberg et al, 2000;Hauben et al, 2000;Fisher et al, 2001). This approach may have wide applicability and effectiveness as shown in animal model systems, including neural trauma, glaucoma, ALS, AD, and PD (Krieger et al, 1976;Charness et al, 1989;Janus et al, 2000;Fisher et al, 2001;Hauben et al, 2001Hauben et al, , 2003Lemere et al, 2001;Weiner and Selkoe, 2002;Bakalash et al, 2003).…”

Treatment with Immunosuppressants FTY720 and Tacrolimus Promotes Functional Recovery after Spinal Cord Injury in Rats

“…Spinal cord injury was induced using a weight-drop device developed at New York University (Gruner 1992) following a protocol developed by a multicenter consortium (Multicenter Animal Spinal Cord Injury Study; Basso et al 1995), which has been reported previously (Hauben et al 2001). Rats were anesthetized with pentobarbital (50 mg/kg, i.p.…”